ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.

Wu, Chengde; Rao, Xiang; Lin, Wei
Cancer Med2021-2DOI: 10.1002/cam4.3655
10阅读
引用收藏
分享

摘要

PURPOSE: TP53 mutation, one of the most frequent mutations in early-stage lung adenocarcinoma (LUAD), triggers a series of alterations in the immune landscape, progression, and clinical outcome of early-stage LUAD. Our study was designed to unravel the effects of TP53 mutation on the immunophenotype of early-stage LUAD and formulate a TP53-associated immune prognostic model (IPM) that can estimate prognosis in early-stage LUAD patients. MATERIALS AND METHODS: Immune-associated differentially expressed genes (DEGs) between TP53 mutated (TP53(MUT) ) and TP53 wild-type (TP53(WT) ) early-stage LUAD were comprehensively analyzed. Univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) analysis identified the prognostic immune-associated DEGs. We constructed and validated an IPM based on the TCGA and a meta-GEO composed of GSE72094, GSE42127, and GSE31210, respectively. The CIBERSORT algorithm was analyzed for assessing the percentage of immune cell types. A nomogram model was established for clinical application. RESULTS: TP53 mutation occurred in approximately 50.00% of LUAD patients, stimulating a weakened immune response in early-stage LUAD. Sixty-seven immune-associated DEGs were determined between TP53(WT) and TP53(MUT) cohort. An IPM consisting of two prognostic immune-associated DEGs (risk score = 0.098 * ENTPD2 expression + 0.168 * MIF expression) was developed through 397 cases in the TCGA and further validated based on 623 patients in a meta-GEO. The IPM stratified patients into low or high risk of undesirable survival and was identified as an independent prognostic indicator in multivariate analysis (HR = 2.09, 95% CI: 1.43-3.06, p < 0.001). Increased expressions of PD-L1, CTLA-4, and TIGIT were revealed in the high-risk group. Prognostic nomogram incorporating the IPM and other clinicopathological parameters (TNM stage and age) achieved optimal predictive accuracy and clinical utility. CONCLUSION: The IPM based on TP53 status is a reliable and robust immune signature to identify early-stage LUAD patients with high risk of unfavorable survival.

学科与关键词

关键词
CIBERSORTTP53early-stage lung adenocarcinomaimmune prognostic modelprognosis
相关
加载中…
  • Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction
    Zhang, Sainan; Li, Mengyue; Tan, Yilong; Zhang, Juxuan; Liu, Yixin; Jiang, Wenbin; Li, Xin; Qi, Haitao; Tang, Lefan; Ji, Ran; Zhao, Wenyuan; Gu, Yunyan*; Qi, Lishuang*Journal of Molecular Medicine, 2022, 100(12): 1755-1769.
  • Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis
    Liu, Mengfeng; Xiao, Qifan; Yu, Xiran; Zhao, Yujie; Qu, Changfa*Frontiers in Pharmacology, 2022, 13: 1081244.
  • Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
    Sun, Hao; Liu, Si-Yang; Zhou, Jia-Ying; Xu, Jin-Tian; Zhang, Huang-Kai; Yan, Hong-Hong; Huan, Jiao-Jiao; Dai, Ping-Ping; Xu, Chong-Rui; Su, Jian; Guan, Yan-Fang; Yi, Xin; Yu, Rong-Shan; Zhong, Wen-Zhao; Wu, Yi-Long*EBioMedicine, 2020, 60: 102990.被引 89
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Med
发表日期
2021-02
卷期
第 10 卷, 第 3 期
页码
806-823
DOI
10.1002/cam4.3655
成果收录
PUBMED

作者

  • W

    Wu, Chengde (第一作者)

  • R

    Rao, Xiang

查看全部 3 位作者收起作者
  • L

    Lin, Wei

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417